The Muscle Atrophy drugs in development market research report provides comprehensive information on the therapeutics under development for Muscle Atrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Muscle Atrophy. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Muscle Atrophy and features dormant and discontinued products.
GlobalData tracks 13 drugs in development for Muscle Atrophy by 11 companies/universities/institutes. The top development phase for Muscle Atrophy is preclinical with nine drugs in that stage. The Muscle Atrophy pipeline has 11 drugs in development by companies and two by universities/ institutes. Some of the companies in the Muscle Atrophy pipeline products market are: Emmyon, Biostar Stem Cell Research Institute and BioAge Labs.
The key targets in the Muscle Atrophy pipeline products market include Cyclic AMP Dependent Transcription Factor ATF 4 (Activating Transcription Factor 4 or Cyclic AMP Responsive Element Binding Protein 2 or DNA Binding Protein TAXREB67 or Tax Responsive Enhancer Element Binding Protein 67 or CREB2 or ATF4), E3 Ubiquitin Protein Ligase TRIM63 (Iris RING Finger Protein or Muscle Specific RING Finger Protein 1 or RING Finger Protein 28 or RING Type E3 Ubiquitin Transferase TRIM63 or Striated Muscle RING Zinc Finger Protein or Tripartite Motif Containing Protein 63 or MURF1 or TRIM63 or EC 2.3.2.27), and F Box Only Protein 32 (Atrogin 1 or Muscle Atrophy F Box Protein or FBXO32).
The key mechanisms of action in the Muscle Atrophy pipeline product include Cyclic AMP Dependent Transcription Factor ATF 4 (Activating Transcription Factor 4 or Cyclic AMP Responsive Element Binding Protein 2 or DNA Binding Protein TAXREB67 or Tax Responsive Enhancer Element Binding Protein 67 or CREB2 or ATF4) Inhibitor with two drugs in Preclinical. The Muscle Atrophy pipeline products include three routes of administration with the top ROA being Oral and six key molecule types in the Muscle Atrophy pipeline products market including Small Molecule, and Antisense RNAi Oligonucleotide.
Muscle Atrophy overview
Muscle atrophy is the wasting or loss of muscle tissue. Symptoms of muscle atrophy include muscle damage, pain, weak muscles, loss of movement, facial weakness, and numbness or tingling in arms or legs. Causes include aging, nerve diseases, stroke, motor neuropathy, muscular dystrophy, and arthritis. Treatment includes exercise, dietary changes, and surgery.
For a complete picture of Muscle Atrophy’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
